Biosplice and Novo Nordisk Collaborate on Diabetes Solutions
Friday, June 14, 2024
Biosplice Therapeutics, Inc., a leader in biotechnology, specializes in creating innovative treatments through the use of small-molecule inhibition targeting DYRK/CLK kinases. Recently, Biosplice has formed a strategic alliance with Novo Nordisk to develop new pharmaceutical candidates aimed at diabetes treatment. This partnership utilizes Biosplice's cutting-edge research, bolstered by substantial scientific backing, which highlights the ability of DYRK inhibition to enhance β-cell proliferation in both animal models and human islet cells. This represents a promising strategy for diabetes management. The collaboration blends Novo Nordisk's expertise in diabetes care with Biosplice’s advancements in selective and potent DYRK inhibitors.
According to the agreement, Novo Nordisk will support the preclinical development of these potential treatments and has obtained an exclusive option to license Biosplice’s relevant intellectual property concerning cardiometabolic disorders. While the financial specifics remain confidential, the agreement includes upfront payments, milestone achievements, and royalties for the license.
Biosplice commented on the partnership, expressing excitement about integrating their specialized DYRK inhibition techniques with Novo Nordisk’s leadership in diabetes treatment. He highlighted that Biosplice has spent over a decade developing therapies aimed at restoring the functionality of human β-cells, offering potential relief for millions of diabetes patients globally. This collaboration marks an exciting chapter in their ongoing efforts to innovate in the field.
Biosplice’s management team believes that their selective DYRK inhibitors, which have shown promising results in preclinical testing involving animal models and human islet cells, could pioneer new therapies for diabetes by addressing the core issues of insulin production in dysfunctional pancreatic β-cells.
The DYRK kinases' role in β-cell proliferation is crucial, and this therapeutic approach aims to surpass current treatments by tackling the fundamental causes of diabetes. Biosplice plans to present some of its preclinical results from these studies at the upcoming American Diabetes Association conference in Orlando, Florida, on June 23 at 12:30 pm.
Additionally, Biosplice is exploring the potential therapeutic applications of DYRK inhibition in treating neurodegenerative diseases linked to tau protein aggregation, such as Alzheimer’s disease and multiple sclerosis, through a partnership with The Roskamp Institute.
Biosplice is committed to developing highly selective and potent DYRK inhibitors designed to stimulate the proliferation of insulin-producing β-cells. This advancement could significantly improve diabetes treatment by enhancing pancreatic islet function and refining glucose regulation, thereby addressing critical challenges in managing both type 1 and type 2 diabetes. Preliminary results in animal models and human islet cells suggest that Biosplice’s compounds have substantial potential to advance diabetes therapies.
Source: globenewswire.com
